[Form 4] Idexx Laboratories Inc Insider Trading Activity
Idexx Laboratories insider Form 4: Jonathan Jay Mazelsky, identified as President and CEO and a director, reported a disposal of 1,051 shares of Idexx common stock on 08/15/2025. The form shows 1,051 shares disposed and 82,443.3016 shares beneficially owned following the transaction. The filing was signed by Lily J. Lu as Attorney-in-Fact on 09/04/2025.
Modulo Form 4 insider di Idexx Laboratories: Jonathan Jay Mazelsky, indicato come Presidente, CEO e membro del consiglio, ha dichiarato la cessione di 1.051 azioni ordinarie Idexx il 15/08/2025. Il modulo indica 1.051 azioni cedute e 82.443,3016 azioni possedute a beneficio dopo la transazione. La documentazione 猫 stata firmata da Lily J. Lu in qualit脿 di Procuratore il 04/09/2025.
Formulario Form 4 de insider de Idexx Laboratories: Jonathan Jay Mazelsky, identificado como Presidente, CEO y director, inform贸 la enajenaci贸n de 1.051 acciones ordinarias de Idexx el 15/08/2025. El formulario muestra 1.051 acciones enajenadas y 82.443,3016 acciones de titularidad beneficiaria tras la transacci贸n. El documento fue firmado por Lily J. Lu como Apoderada el 04/09/2025.
Idexx Laboratories 雮措秬鞛� Form 4: 須岇灔 瓴� CEO鞚挫瀽 鞚挫偓搿� 旮办灛霅� Jonathan Jay Mazelsky臧� 2025-08-15鞐� Idexx 氤错喌欤� 1,051欤茧ゼ 觳橂秳頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 靹滊鞐愲姅 瓯半灅 頉� 觳橂秳 欤检嫕 1,051欤�鞕赌 靻岇湢 鞚挫澋 旮办 82,443.3016欤�臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞁犼碃靹滊姅 Lily J. Lu臧� 鞙勳瀯雽�毽澑(Attorney-in-Fact)鞙茧靹� 2025-09-04鞐� 靹滊獏頄堨姷雼堧嫟.
Formulaire Form 4 d'initi茅 d'Idexx Laboratories聽: Jonathan Jay Mazelsky, identifi茅 comme pr茅sident, directeur g茅n茅ral et administrateur, a d茅clar茅 la cession de 1鈥�051 actions ordinaires Idexx le 15/08/2025. Le formulaire indique 1鈥�051 actions c茅d茅es et 82鈥�443,3016 actions d茅tenues 脿 titre b茅n茅ficiaire apr猫s la transaction. Le dossier a 茅t茅 sign茅 par Lily J. Lu en qualit茅 de mandataire le 04/09/2025.
Idexx Laboratories Insider-Formular 4: Jonathan Jay Mazelsky, angegeben als Pr盲sident, CEO und Direktor, meldete am 15.08.2025 die Ver盲u脽erung von 1.051 Aktien der Idexx-Stammaktien. Das Formular weist 1.051 ver盲u脽erte Aktien und 82.443,3016 wirtschaftlich gehaltene Aktien nach der Transaktion aus. Die Einreichung wurde am 04.09.2025 von Lily J. Lu als Bevollm盲chtigte unterzeichnet.
- Disclosure completed: The reporting person filed a Form 4 documenting the transaction, meeting Section 16 reporting requirements
- Substantial retained ownership: Reporting person retains 82,443.3016 shares following the reported disposition
- Disposition reported: A sale/disposition of 1,051 shares occurred on 08/15/2025
- Price field shows $0: The filing lists a price of $0 for the non-derivative disposition without further explanation
Insights
TL;DR: Insider sale of 1,051 shares reported; remaining beneficial ownership remains sizable at 82,443.3016 shares.
The Form 4 documents a single non-derivative disposition by Jonathan Jay Mazelsky on 08/15/2025 of 1,051 shares of IDEXX common stock. The filing lists the transaction code as "G" and reports 82,443.3016 shares beneficially owned after the sale. This is a routine Section 16 disclosure reflecting an insider sale; no derivative transactions or prices beyond a reported $0 are provided in the filing. The explicit figures allow verification of ownership changes but do not include proceeds or the reason for the sale.
TL;DR: Director and CEO reported a small share disposition; disclosure complies with Section 16 reporting requirements.
The filing identifies Mazelsky as both an officer and director and records a reported disposal of 1,051 shares on 08/15/2025, with beneficial ownership remaining at 82,443.3016 shares. The document is signed by an Attorney-in-Fact and contains no amendments or additional remarks. From a governance and compliance perspective, the Form 4 fulfills the statutory reporting obligation but contains limited context about the transaction type or price beyond the table entry showing $0, which is presented without explanation in the filing.
Modulo Form 4 insider di Idexx Laboratories: Jonathan Jay Mazelsky, indicato come Presidente, CEO e membro del consiglio, ha dichiarato la cessione di 1.051 azioni ordinarie Idexx il 15/08/2025. Il modulo indica 1.051 azioni cedute e 82.443,3016 azioni possedute a beneficio dopo la transazione. La documentazione 猫 stata firmata da Lily J. Lu in qualit脿 di Procuratore il 04/09/2025.
Formulario Form 4 de insider de Idexx Laboratories: Jonathan Jay Mazelsky, identificado como Presidente, CEO y director, inform贸 la enajenaci贸n de 1.051 acciones ordinarias de Idexx el 15/08/2025. El formulario muestra 1.051 acciones enajenadas y 82.443,3016 acciones de titularidad beneficiaria tras la transacci贸n. El documento fue firmado por Lily J. Lu como Apoderada el 04/09/2025.
Idexx Laboratories 雮措秬鞛� Form 4: 須岇灔 瓴� CEO鞚挫瀽 鞚挫偓搿� 旮办灛霅� Jonathan Jay Mazelsky臧� 2025-08-15鞐� Idexx 氤错喌欤� 1,051欤茧ゼ 觳橂秳頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 靹滊鞐愲姅 瓯半灅 頉� 觳橂秳 欤检嫕 1,051欤�鞕赌 靻岇湢 鞚挫澋 旮办 82,443.3016欤�臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞁犼碃靹滊姅 Lily J. Lu臧� 鞙勳瀯雽�毽澑(Attorney-in-Fact)鞙茧靹� 2025-09-04鞐� 靹滊獏頄堨姷雼堧嫟.
Formulaire Form 4 d'initi茅 d'Idexx Laboratories聽: Jonathan Jay Mazelsky, identifi茅 comme pr茅sident, directeur g茅n茅ral et administrateur, a d茅clar茅 la cession de 1鈥�051 actions ordinaires Idexx le 15/08/2025. Le formulaire indique 1鈥�051 actions c茅d茅es et 82鈥�443,3016 actions d茅tenues 脿 titre b茅n茅ficiaire apr猫s la transaction. Le dossier a 茅t茅 sign茅 par Lily J. Lu en qualit茅 de mandataire le 04/09/2025.
Idexx Laboratories Insider-Formular 4: Jonathan Jay Mazelsky, angegeben als Pr盲sident, CEO und Direktor, meldete am 15.08.2025 die Ver盲u脽erung von 1.051 Aktien der Idexx-Stammaktien. Das Formular weist 1.051 ver盲u脽erte Aktien und 82.443,3016 wirtschaftlich gehaltene Aktien nach der Transaktion aus. Die Einreichung wurde am 04.09.2025 von Lily J. Lu als Bevollm盲chtigte unterzeichnet.
FAQ
What transaction did Jonathan Jay Mazelsky report on Form 4 for IDXX?
How many IDEXX shares does the reporting person own after the reported transaction?
When was the Form 4 signed and who signed it?
Does the Form 4 show exercise of options or derivative transactions for IDXX?
Is the transaction coded and dated in the filing?
